SCHEMBL19100647

SCHEMBL19100647

N#Cc1cnc(Cl)nc1-n1ncc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 2/20 0.45
▸ CSNK1A1 P48729 1/20 0.43
▸ CLK4 Q9HAZ1 1/20 0.43
▸ CYP1A2 P05177 1/20 0.38
▸ PDE10A Q9Y233 3/20 0.38
▸ NR3C1 P04150 1/20 0.37
▸ RECQL P46063 1/20 0.35
▸ RPS6KA5 O75582 3/20 0.35
▸ RPS6KA4 O75676 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MKNK1 Q9BUB5 2/20 0.34
▸ MKNK2 Q9HBH9 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ MGAM O43451 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SI P14410 1/20 0.33
▸ MGAM2 Q2M2H8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19100791 0.81 RPS6KA5 (0.48) PDE10ARECQLRPS6KA5RPS6KA4RAB9A
SCHEMBL28612234 0.78 RPS6KA5 (0.46) PIN1CSNK1A1CLK4RPS6KA5RPS6KA4
SCHEMBL19100753 0.76 CSNK1A1 (0.49) PIN1CSNK1A1CLK4CYP1A2RAB9A
SCHEMBL22695443 0.76 PIN1 (0.41) PIN1CSNK1A1CLK4CYP1A2RPS6KA5
SCHEMBL19100325 0.76 PIN1 (0.41) PIN1CSNK1A1CLK4RPS6KA5RPS6KA4
SCHEMBL19100490 0.75 RPS6KA5 (0.39) PDE10ANR3C1RECQLRPS6KA5RPS6KA4
SCHEMBL20479193 0.74 MKNK1 (0.58) PIN1RPS6KA5RPS6KA4MKNK1MKNK2
SCHEMBL19100643 0.74 PIN1 (0.41) PIN1CSNK1A1CLK4RAB9AALDH1A1
SCHEMBL28612373 0.71 PIN1 (0.41) PIN1CSNK1A1CLK4RPS6KA5RPS6KA4
SCHEMBL28612361 0.71 CSNK1A1 (0.46) PIN1CSNK1A1CLK4RPS6KA5RPS6KA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3399968-B1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LTD (KY) 2021-10-20 — — EP disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed
EP-3399968-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmatech Limited (KY) 2018-11-14 — — EP disclosed
WO-2017120429-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmasciences, Inc. (US) 2017-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 PIN1 768/4885CSNK1A1 24/4885CLK4 1783/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 PIN1 768/4885CSNK1A1 24/4885CLK4 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback